Home | Site Index | Contact Us  
 
The Valeant R&D Portfolio includes many development and marketed products across three therapy areas of interest: Infectious Disease, Neurology and Dermatology.

To learn more about these products, please click on the name shown on the R&D Portfolio chart below.

Therapeutic Areas Discovery / Pre-clinical Phase 1 Phase 2 Phase 3 Lifecycle Management Click here to learn more about Infectious Disease Click here to learn more about Taribavirin Click here to learn more about Neurology Click here to learn more about Retigabine Click Click here to learn more about Retigabine Click here to learn more about Retigabine Click here to learn more about Retigabine Click here to learn more about Tasmar Click here to learn more about Zelapar Click here to learn more about Migranal Click here to learn more about Dermatology Click here to learn more about Kinerase Click here to learn more about Dermatix

TARIBAVIRIN and RETIGABINE are products in clinical development. None of them have been found to be safe or effective for the treatment of any disease or illness. They may not be sold or promoted in the United States unless and until they are approved by the FDA. Similar restrictions apply in other countries.

© Valeant Pharmaceuticals International 2007
Legal and Privacy Statement